Interestingly, as opposed to the rosiglitazone treatment which slightly decreases severe malaria infection, we demonstrated here for the first time that the SFN, an Nrf2 activator, strongly contributes to control the elevation of parasite burden and hence consistently improves the outcome of severe inflammatory induced-malaria. Here, NFE2L2 is linked to malaria.